4.2 Article

Dysbiosis in gastrointestinal disorders

Journal

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2016.02.001

Keywords

Dysbiosis; Microbiota; Microbiome; Metagenomics; Metabolomics; Obesity; Nonalcoholic fatty liver disease; Inflammatory bowel disease; Irritable bowel syndrome

Funding

  1. Winkler Bacterial Overgrowth Research Fund

Ask authors/readers for more resources

The recent development of advanced sequencing techniques has revealed the complexity and diverse functions of the gut micro biota. Furthermore, alterations in the composition or balance of the intestinal microbiota, or dysbiosis, are associated with many gastrointestinal diseases. The looming question is whether dysbiosis is a cause or effect of these diseases. In this review, we will evaluate the contribution of intestinal microbiota in obesity, fatty liver, inflammatory bowel disease, and irritable bowel syndrome. Promising results from microbiota or metabolite transfer experiments in animals suggest the microbiota may be sufficient to reproduce disease features in the appropriate host in certain disorders. Less compelling causal associations may reflect complex, multi-factorial disease pathogenesis, in which dysbiosis is a necessary condition. Understanding the contributions of the microbiota in GI diseases should offer novel insight into disease pathophysiology and deliver new treatment strategies such as therapeutic manipulation of the microbiota. (C) 2016 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available